{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:02:55Z","timestamp":1789632175166,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102436","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:24:33Z","timestamp":1757859873000},"page":"102436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6651-2189","authenticated-orcid":false,"given":"Matthew","family":"Steidle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8987","authenticated-orcid":false,"given":"Kamil","family":"Malshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2439-7578","authenticated-orcid":false,"given":"Trevor C.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-7585","authenticated-orcid":false,"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4041-0556","authenticated-orcid":false,"given":"Ashley","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Doersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102436_bib0001","unstructured":"FDA. Milestones in U.S. Food Drug Law. November 2, 2025. Available at: https:\/\/www.fda.gov\/about-fda\/fda-history\/milestones-us-food-and-drug-law."},{"issue":"9","key":"10.1016\/j.clgc.2025.102436_bib0002","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2025.102436_bib0003","unstructured":"U.S. Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. US Food Drug Administration. 2018. November 2, 2025. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics."},{"issue":"3","key":"10.1016\/j.clgc.2025.102436_bib0004","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1602\/neurorx.1.3.323","article-title":"Evidence from biomarkers and surrogate endpoints","volume":"1","author":"Feigin","year":"2004","journal-title":"NeuroRX"},{"issue":"S1","key":"10.1016\/j.clgc.2025.102436_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2010-S1-13","article-title":"The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology","volume":"15","author":"McKee","year":"2010","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clgc.2025.102436_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/PPO.0b013e3181bdc2e0","article-title":"Overall survival: still the gold standard: why Overall survival remains the definitive end point in cancer clinical trials","volume":"15","author":"Driscoll","year":"2009","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.clgc.2025.102436_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3747\/co.20.1226","article-title":"Overall survival should Be the primary endpoint in clinical trials for advanced non-small-cell lung cancer","volume":"20","author":"Cheema","year":"2013","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102436_bib0008","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clgc.2025.102436_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2023.01.002","article-title":"Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: a review","volume":"177","author":"Blakely","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clgc.2025.102436_bib0010","unstructured":"CT.GOV. ClinicalTrials.Gov glossary terms. November 2, 2025. Available at: https:\/\/clinicaltrials.gov\/study-basics\/glossary."},{"key":"10.1016\/j.clgc.2025.102436_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00194","article-title":"Impact of industry collaboration on US Food and Drug Administration approval success in genitourinary malignancy phase III clinical trials","author":"Malshy","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.clgc.2025.102436_bib0012","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/OP.23.00363","article-title":"Probability of regulatory approval over time: a cohort study of cancer therapies","volume":"20","author":"Hutchinson","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.clgc.2025.102436_bib0013","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102436_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing Atezolizumab plus Bevacizumab vs Sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.clgc.2025.102436_bib0015","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.2217\/fon-2020-1133","article-title":"KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer","volume":"17","author":"Petrylak","year":"2021","journal-title":"Future Oncol"},{"issue":"10295","key":"10.1016\/j.clgc.2025.102436_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.clgc.2025.102436_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","volume":"21","author":"Petrylak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2025.102436_bib0018","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clgc.2025.102436_bib0019","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant Pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102436_bib0020","series-title":"Urogen announces unprecedented 82.3% duration of response at 12 months","year":"2024"},{"issue":"7","key":"10.1016\/j.clgc.2025.102436_bib0021","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2025.102436_bib0022","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2024.42.4_suppl.588","article-title":"Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer","volume":"42","author":"Golijanin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102436_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102436_bib0024","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102436_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013Muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.clgc.2025.102436_bib0026","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-21-2334","article-title":"FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma","volume":"28","author":"Chang","year":"2022","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.clgc.2025.102436_bib0027","series-title":"FDA approves niraparib for HRD-positive advanced ovarian cancer","year":"2019"},{"key":"10.1016\/j.clgc.2025.102436_bib0028","unstructured":"Cancer Network. FDA approves Gemzar\/Carboplatin for advanced ovarian Ca. Available at: https:\/\/www.cancernetwork.com\/view\/fda-approves-gemzarcarboplatin-advanced-ovarian-ca. Accessed September 9, 2025."},{"issue":"3","key":"10.1016\/j.clgc.2025.102436_bib0029","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2019.09.026","article-title":"Roed H. Gemcitabine for recurrent ovarian cancer\u2014a systematic review and meta-analysis","volume":"155","author":"Berg","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102436_bib0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12885-021-08457-5","article-title":"Food and Drug Administration approvals in phase 3 cancer clinical trials","volume":"21","author":"Abi Jaoude","year":"2021","journal-title":"BMC Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:08:35Z","timestamp":1770671315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001363"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102436","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102436"}}